UCB SA (OTCMKTS:UCBJF) Short Interest Update

UCB SA (OTCMKTS:UCBJF) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 403,500 shares, a decrease of 17.0% from the October 15th total of 486,100 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 4,035.0 days.

UCB Stock Down 10.1 %

UCB stock opened at $175.00 on Friday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average of $181.79 and a two-hundred day moving average of $157.92. UCB has a one year low of $72.25 and a one year high of $194.76.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.